Loading
As the first KRAS G12C drugs arrived, this study described the patients they would treat: about one in six KRAS-mutant bowel cancers, more often men, more often with lung and liver spread, and with shorter survival than other KRAS mutations.
Clinicopathological features and outcome data for KRAS-mutant metastatic colorectal cancer patients referred to three Italian oncology units between January 2010 and December 2018 were collected, with a separate Milan cohort as external validation. Of 839 KRAS-mutant patients in the main population, 145 (17%) had a KRAS G12C mutation. G12C patients were more likely to be men and to present with lung and liver metastases, and less likely to have peritoneal spread. KRAS G12C mutation was associated with shorter overall survival than other KRAS mutations (hazard ratio 1.32), a result confirmed in the external validation cohort.
It defines the population the G12C inhibitors address and sets the baseline against which CodeBreaK 300 and KRYSTAL-1 are read.
Shares CodeBreaK 300, Adagrasib, Sotorasib, KRAS & RAS inhibitors.
Shares KRAS G12C, Adagrasib, KRAS & RAS inhibitors, RAS / RAF / MEK / ERK (MAPK).
Shares CodeBreaK 300, Sotorasib, KRAS & RAS inhibitors, Colorectal cancer.
Shares KRAS G12C, Sotorasib, KRAS & RAS inhibitors, RAS / RAF / MEK / ERK (MAPK).
Shares CodeBreaK 300, KRAS G12C, Sotorasib, KRAS & RAS inhibitors.
Shares Adagrasib, Sotorasib, KRAS & RAS inhibitors, KRAS.
Shares KRAS G12C, Adagrasib, KRAS & RAS inhibitors, KRAS.
Shares Adagrasib, Sotorasib, KRAS & RAS inhibitors, KRAS.